Literature DB >> 35064332

Is There a Relationship Between TILs and Regression in Melanoma?

Steven Morrison1, Gang Han2, Faith Elenwa2, John T Vetto3, Graham Fowler1, Stanley P Leong4, Mohammed Kashani-Sabet4, Barbara Pockaj5, Heidi E Kosiorek5, Jonathan S Zager6,7, Jane L Messina6, Nicola Mozzillo8, Schlomo Schneebaum9, Dale Han1.   

Abstract

BACKGROUND: The relationship between tumor-infiltrating lymphocytes (TILs) and regression in melanoma is unknown. This report describes a large multicenter study assessing the association between TILs and regression.
METHODS: The Sentinel Lymph Node Working Group database was queried from 1993 to 2018 for cases with TILs and regression data. Clinicopathologic factors were correlated with regression and TIL status, sentinel lymph node (SLN) status, and overall survival (OS).
RESULTS: The study enrolled 2450 patients. In 1811 cases, TILs (73.9%) were present, with regression present in 328 of these 1811 (18.1%) cases and in 49 (7.7%) of 639 cases without TILs. The presence of TILs was significantly associated with regression (p < 0.0001) as well as a negative SLN (p < 0.05). However, when TILs were stratified by regression status, only absence or presence of both TILs and regression were significantly associated with SLN metastases (p = 0.038). Although the presence of TILs was associated with OS (p < 0.05), regression status by itself was not (p = 0.2058 and 0.252, respectively). Furthermore, when TILs were stratified by regression status, only the presence of TILs with or without regression was significantly associated with improved OS (p = 0.0081 and 0.0137, respectively) versus the absence of both TILs and regression, with regression status not significantly affecting OS for patients with or without TILs (p = 0.2314 and 0.65, respectively).
CONCLUSIONS: Regression is highly correlated with TILs, but only TILs are significantly associated with SLN metastasis and OS in melanoma patients, whereas regression is not. The impact of regression on outcomes ultimately appears dependent upon the absence or presence of TILs.
© 2022. Society of Surgical Oncology.

Entities:  

Keywords:  Melanoma; Regression; Tumor-infiltrating lymphocytes (TIL)

Mesh:

Year:  2022        PMID: 35064332     DOI: 10.1245/s10434-021-11251-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  52 in total

1.  Predicting five-year outcome for patients with cutaneous melanoma in a population-based study.

Authors:  R L Barnhill; J A Fine; G C Roush; M Berwick
Journal:  Cancer       Date:  1996-08-01       Impact factor: 6.860

2.  Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.

Authors:  Nancy E Thomas; Klaus J Busam; Lynn From; Anne Kricker; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Terence Dwyer; Alison Venn; Peter A Kanetsky; Pamela A Groben; Honglin Hao; Irene Orlow; Anne S Reiner; Li Luo; Susan Paine; David W Ollila; Homer Wilcox; Colin B Begg; Marianne Berwick
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

Review 3.  Tumor infiltrating lymphocytes: The regulator of melanoma evolution.

Authors:  Mihaela Antohe; Roxana Ioana Nedelcu; Luciana Nichita; Cristiana Gabriela Popp; Mirela Cioplea; Alice Brinzea; Anastasia Hodorogea; Andreea Calinescu; Mihaela Balaban; Daniela Adriana Ion; Carmen Diaconu; Coralia Bleotu; Daniel Pirici; Sabina Andrada Zurac; Gabriela Turcu
Journal:  Oncol Lett       Date:  2019-01-16       Impact factor: 2.967

4.  Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.

Authors:  Rebecca C Taylor; Ami Patel; Katherine S Panageas; Klaus J Busam; Mary S Brady
Journal:  J Clin Oncol       Date:  2007-03-01       Impact factor: 44.544

5.  Prognostic significance of tumor infiltrating lymphocytes in melanoma.

Authors:  Alison L Burton; Brent A Roach; Michael P Mays; Andrea F Chen; Brooke A R Ginter; Abbey M Vierling; Charles R Scoggins; Robert C G Martin; Arnold J Stromberg; Lee Hagendoorn; Kelly M McMasters
Journal:  Am Surg       Date:  2011-02       Impact factor: 0.688

6.  Model predicting survival in stage I melanoma based on tumor progression.

Authors:  W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

7.  Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.

Authors:  C G Clemente; M C Mihm; R Bufalino; S Zurrida; P Collini; N Cascinelli
Journal:  Cancer       Date:  1996-04-01       Impact factor: 6.860

8.  Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.

Authors:  M Mandalà; G L Imberti; D Piazzalunga; M Belfiglio; R Labianca; M Barberis; L Marchesi; P Poletti; L Bonomi; L Novellino; K Di Biagio; A Milesi; U Guerra; C Tondini
Journal:  Eur J Cancer       Date:  2009-06-22       Impact factor: 9.162

9.  Absence of Tumor-Infiltrating Lymphocyte Is a Reproducible Predictive Factor for Sentinel Lymph Node Metastasis: A Multicenter Database Study by the Brazilian Melanoma Group.

Authors:  João Pedreira Duprat; Eduard René Brechtbülh; Bianca Costa de Sá; Mauro Enokihara; Jose Humberto Fregnani; Gilles Landman; Marcus Maia; Felice Riccardi; Francisco Alberto Belfort; Alberto Wainstein; Luciana F Moredo; Higino Steck; Miguel Brandão; Marcelo Moreno; Eduardo Miranda; Ivan Dunshee de Oliveira Santos
Journal:  PLoS One       Date:  2016-02-09       Impact factor: 3.240

10.  A Retrospective, Observational Analysis of Tumor Infiltrating Lymphocytes and Tumor Regression in Melanoma.

Authors:  Angela Zaladonis; Jeffrey Farma; Maureen Hill; Meghan Hotz; Karli Meller; Tamsin Board; Mengying Deng; Hong Wu; Sanjay Reddy; Eileen O'Halloran
Journal:  J Surg Res       Date:  2021-06-18       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.